Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.

Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
Albumin bound paclitaxel: Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.

Albumin Bound Paclitaxel

Sex: Female, Male

Region of Enrollment

Patients with clinically diagnosed mucinous cysts (premalignant or malignant cysts of the pancreas) including mucinous cystic neoplasms and intraductal papillary mucinous neoplasms were eligible.

Cyst diameter

Location of cyst

Safety of injection of albumin-bound paclitaxel will be measured by the frequency of pancreatitis.

Frequency of Pancreatitis

The feasibility of the procedure will be measured by the ease of injection of albumin-bound paclitaxel into the cyst cavity across the gastro-duodenal wall. On a subjective scale, the endoscopist will note the ease of the procedure on a scale of 0-5, with 5 being very easy and 0 is not possible. Any score less than 2 will be considered unacceptable and failure of the study.

Feasibility of Endoscopic Ultrasonography (EUS) Guided Injection of Albumin-bound Paclitaxel Into Pancreatic Cysts

Determine the size of the cystic lesion using CT scanning. Number of participants with reduction in size, persistent size, or increase in size of cyst are reported.

Size of Cystic Lesion

Overall Study

Dr. William Brugge

Pancreatic Cysts

Albumin bound paclitaxel

Endoscopic Abraxane Injection Into Pancreatic Cysts

EUS Guided Injection of Albumin Bound Paclitaxel Into Pancreatic Cysts

William R. Brugge, MD

Principal Investigator

Massachusetts General Hospital

Giardiasis

Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)

Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)

Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole

Anti-Giardia treatment only (secnidazole or albendazole)

Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo

Control group (placebo)

National Institute of Preventive and Social Medicine

Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

Effects of Anti-Giardia and Antihelmintic Treatment on Infant Nutritional and Biochemical Status and Intestinal Permeability in Rural Bangladesh

Dr Rie Goto

University of Cambridge

Pravastatin
pravastatin: Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)

Pravastatin

Placebo

Total

Total kidney volume corrected for height (HtTKV, ml/m)

Total kidney volume corrected for height

Urinary albumin excretion

Left ventricular mass index in g/m^2 by MRI

Left ventricular mass index

Total cholesterol

LDL cholesterol

Percent of participants demonstrating 20% or more increase in total kidney volume corrected for height, left ventricular mass index, or urinary albumin excretion over the three year study period

Percent of Participants Demonstrating 20% or More Increase in Total Kidney Volume

Percentage Change in Total Kidney Volume Corrected for Height

left ventricular mass index in g/m^2 by MRI

Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)

Left Ventricular Mass Index

Urinary Albumin Excretion

Melissa Cadnapaphornchai, MD

Polycystic Kidney, Autosomal Dominant

pravastatin

University of Colorado at Denver and Health Sciences Center

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease

University of Colorado, Denver

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).

Long-acting somatostatin

Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).

Saline solution

Hospital "Ospedali Riuniti" Unit of Nephrology and Dialysis

Hospital "V. Fazzi" - Unit of neprology and Dialysis

Hospital "Presidio Osp. Maggiore Policlinico"

University "Federico II" of Naples

Hospital Cà Foncello

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study

cysts/albumin

Endoscopic Abraxane Injection Into Pancreatic Cysts

Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen